PMCC-COE-KMA

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NamePMCC-COE-KMA

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Donor > Autologous +[4]

Mechanisms of ActionKappa Myeloma antigen modulators

TargetsKappa Myeloma antigen

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesHaemalogix Pty Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHaemalogix Pty Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A